Literature DB >> 27319402

Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.

S Singh1, A K Houng1, D Wang1, G L Reed2.   

Abstract

UNLABELLED: Essentials Physiologic variations in blood plasminogen (Pg) levels may affect ischemic stroke outcomes. We tested Pg effects in a model with translational relevance to human thromboembolic stroke. A dose-response exists between Pg levels and brain injury, fibrinolysis, barrier breakdown. Higher Pg levels reduce microvascular thrombosis and improve outcomes in ischemic stroke.
SUMMARY: Background and Objectives Plasminogen appears to affect brain inflammation, cell movement, fibrinolysis, neuronal excitotoxicity, and cell death. However, brain tissue and circulating blood plasminogen may have different roles, and there is wide individual variation in blood plasminogen levels. The aim of this study was to determine the integrated effect of blood plasminogen levels on ischemic brain injury. Methods We examined thromboembolic stroke in mice with varying, experimentally determined, blood plasminogen levels. Ischemic brain injury, blood-brain barrier breakdown, matrix metalloproteinase-9 expression and microvascular thrombosis were determined. Results Within the range of normal variation, plasminogen levels were strongly associated with ischemic brain injury; higher blood plasminogen levels had dose-related, protective effects. Higher plasminogen levels were associated with increased dissolution of the middle cerebral artery thrombus. Higher plasminogen levels decreased blood-brain barrier breakdown, matrix metalloproteinase-9 expression and microvascular thrombosis in the ischemic brain. In plasminogen-deficient mice, selective restoration of blood plasminogen levels reversed the harmful effects of plasminogen deficiency on ischemic brain injury. Specific inhibition of thrombin also reversed the effect of plasminogen deficiency on ischemic injury by decreasing microvascular thrombosis, blood-brain barrier breakdown, and matrix metalloproteinase-9 expression. Conclusions Variation in blood plasminogen levels, within the range seen in normal individuals, had marked effects on experimental ischemic brain injury. Higher plasminogen levels protected against ischemic brain injury, and decreased blood-brain barrier breakdown, matrix metalloproteinase-9 expression, and microvascular thrombosis. The protective effects of blood plasminogen appear to be mediated largely through a decrease in microvascular thrombosis in the ischemic territory.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  blood-brain barrier; cerebral infarction; matrix metalloproteinase-9; plasminogen; thromboembolism; thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27319402      PMCID: PMC5035596          DOI: 10.1111/jth.13390

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  43 in total

Review 1.  Elements of cerebral microvascular ischaemia.

Authors:  M A Petty; J G Wettstein
Journal:  Brain Res Brain Res Rev       Date:  2001-08

2.  Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  M Fareed K Suri; Kazumasa Yamagishi; Nena Aleksic; Peter J Hannan; Aaron R Folsom
Journal:  Cerebrovasc Dis       Date:  2010-03-19       Impact factor: 2.762

3.  Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin.

Authors:  Guy L Reed; Aiilyan K Houng; Dong Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-25       Impact factor: 8.311

4.  t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes.

Authors:  Be'eri Niego; Roxann Freeman; Till B Puschmann; Ann M Turnley; Robert L Medcalf
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

5.  Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.

Authors:  G L Reed; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

6.  Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.

Authors:  T H Bugge; M J Flick; C C Daugherty; J L Degen
Journal:  Genes Dev       Date:  1995-04-01       Impact factor: 11.361

7.  Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.

Authors:  R Kikumoto; Y Tamao; T Tezuka; S Tonomura; H Hara; K Ninomiya; A Hijikata; S Okamoto
Journal:  Biochemistry       Date:  1984-01-03       Impact factor: 3.162

8.  Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats.

Authors:  Shinji Fujimoto; Hiroshi Katsuki; Masatoshi Ohnishi; Mikako Takagi; Toshiaki Kume; Akinori Akaike
Journal:  J Cereb Blood Flow Metab       Date:  2007-10-17       Impact factor: 6.200

Review 9.  Multiphasic roles for matrix metalloproteinases after stroke.

Authors:  Anna Rosell; Eng H Lo
Journal:  Curr Opin Pharmacol       Date:  2008-01-15       Impact factor: 5.547

Review 10.  Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.

Authors:  John J Sheehan; Stella E Tsirka
Journal:  Glia       Date:  2005-06       Impact factor: 8.073

View more
  7 in total

Review 1.  α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.

Authors:  Guy L Reed; Aiilyan K Houng; Satish Singh; Dong Wang
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

2.  Matrix Metalloproteinase-9 Mediates the Deleterious Effects of α2-Antiplasmin on Blood-Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Stroke.

Authors:  Satish Singh; Aiilyan K Houng; Guy L Reed
Journal:  Neuroscience       Date:  2017-12-30       Impact factor: 3.590

3.  Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of α2-antiplasmin.

Authors:  Satish Singh; Aiilyan K Houng; Guy L Reed
Journal:  Blood       Date:  2019-08-08       Impact factor: 22.113

4.  Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.

Authors:  Sofiyan Saleem; Dong Wang; Tieqiang Zhao; Ryan D Sullivan; Guy L Reed
Journal:  Neuroscience       Date:  2021-01-17       Impact factor: 3.590

5.  Plasminogen Tochigi mice exhibit phenotypes similar to wild-type mice under experimental thrombotic conditions.

Authors:  Yuko Tashima; Fumiaki Banno; Toshiyuki Kita; Yasuyuki Matsuda; Hiroji Yanamoto; Toshiyuki Miyata
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

6.  t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke.

Authors:  Dominik F Draxler; Felix Lee; Heidi Ho; Charithani B Keragala; Robert L Medcalf; Be'eri Niego
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

7.  Proteomics-Based Approach to Identify Novel Blood Biomarker Candidates for Differentiating Intracerebral Hemorrhage From Ischemic Stroke-A Pilot Study.

Authors:  David Malicek; Ilka Wittig; Sebastian Luger; Christian Foerch
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.